ClinicalTrials.gg
Drug

Enasidenib clinical trials

Also written AG-221, Idhifa and CC-90007.

studies test it
36
open now
11
in phase 3
3
first study started
2013

How each study uses enasidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the enasidenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Aug 2017 · IDHIFA · NDA 209606 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Enasidenib
26
CC-90007 Free Base
6
Enasidenib Mesylate
5
2-Methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol Methanesulfonate
5
2-Propanol, 2-Methyl-1-((4-(6-(trifluoromethyl)-2-pyridinyl)-6-((2-(trifluoromethyl)-4-pyridinyl)amino)-1,3,5-triazin-2-yl)amino)-, Methanesulfonate (1:1)
5

Brand

Idhifa
11

Development codes

AG-221
22
CC-90007
7
AGI-12910
2

Studies by the year they started

36 studies that test it; most in 2019 (6)

Studies that test enasidenib, by start year
YearStudies
20131
20142
20154
20162
20171
20184
20196
20203
20213
20221
20233
20244
20252

By phase

A phase 1/2 study counts in both.

Phase 1
18
Phase 2
22
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 10 · Other 26

Celgene (9) · National Cancer Institute (NCI) (4) · Memorial Sloan Kettering Cancer Center (3) · M.D. Anderson Cancer Center (3) · City of Hope Medical Center (2) · Stichting Hemato-Oncologie voor Volwassenen Nederland (1) · Groupe Francophone des Myelodysplasies (1) · Institut de Recherches Internationales Servier (1)

Often tested with

Tested in the same studies.

Ivosidenib (6) · Venetoclax (5) · Azacitidine (4) · Daunorubicin (2) · CPX-351 (2) · Cobimetinib (2) · Cytarabine (2) · Gilteritinib (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 9, 1 in phase 3

Studies that test enasidenib, phase 3 first.

Studies

Open first, then newest update. How each study uses enasidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 36

See all 36 studies that test enasidenib →

Given beside what is tested · 7 — enasidenib is usual care or a partner of the new treatment

Codes

What other systems call enasidenib · ClinicalTrials.gg INT000407

  • MeSH (NLM) C000605269enasidenibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 3T1SS4E7AGENASIDENIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1940332Confirmed FDA, Wikidata
  • Wikidata Q27077182enasidenibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C111573EnasidenibConfirmed FDA, Wikidata
  • DrugBank DB13874One source Wikidata

Also registered as enasidenib mesylate (UNII UF6PC17XAV · RxNorm 1940331).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.